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Innovative Therapies for Pancreatic-Related Cancers
Pancreatic cancer patients come to Thomas Jefferson University Hospital because of the reputation, skill,
and track records of its surgical staff, who perform a high volume of surgeries. However, this patientcentric approach to care is supported by an impressive research capability that also has significant
impact on both the prevention and recovery of pancreatic-related diseases.
Two world-class Jefferson researchers, Hwyda Arafat, MD, PhD, and Jonathan Brody, PhD, are making
tremendous inroads toward understanding the science and genesis of pancreatic-related cancers. Their
goal is to manage or halt the progress of disease through innovative and diverse therapies.

Drs. Brody and Arafat

Dr. Arafat, Assistant Professor of Surgery, has a PhD in cell biology and immunology. A native of Egypt,
she is currently investigating pancreatic cancer as it pertains to the reninangiotensis system involved in
hypertension. She is also interested in the use of antihypertension medications already on the market to
help treat pancreatic cancer. "I have the patient on my mind everyday," she says. "It is my motivation, my
hope that our research can help to make the disease manageable."
In 2005, when Dr. Arafat began a multidisciplinary approach in the lab that expanded her work on
diabetes, she began to see correlations between patients who received hypertension medications and a
decrease in cancer occurrences. "Clinical trials are just a year away that will help us understand whether
the hypertension therapies work, as well as the science behind them," explains Dr. Arafat.
Since joining the Jefferson faculty as Assistant Professor in 2006, Dr. Brody has concentrated on the
complex molecular genetics of pancreatic cancer. After earning a PhD from the Johns Hopkins School of
Medicine, he completed post-doctoral training in oncology with Scott E. Kern, MD, who is world-renowned
for his work in the genetics of pancreatic cancer. Together they revolutionized a basic molecular biology
technique (now patented) called DNA electrophoresis, making it possible to see genetic results five times
faster with cleaner results.

"Clinical trials are just a year away that will help us understand whether
the hypertension therapies work, as well as the science behind them."
A patient's tumor is collected during surgery and then studied in the lab to understand its specific
genetics. Dr. Brody seeks to use this information to develop anti-cancer therapies through medication that
will be suited to the individual patient.
"By studying a tumor's genesis, we can begin to understand the series of events that led up to making a
cell cancerous," he says. "We will then have isolated the molecular defects-what went wrong-and can find
a better, more targeted, and sophisticated approach for drug therapies." Dr. Brody explained that, just as
we now know which antibiotics work best for specific bacterial strains, "we are striving to do the same for
pancreatic cancers, and we are already seeing some very positive results."
Doctors Arafat and Brody are at the forefront of research in the field today. Dr. Arafat was one of the
Jefferson physicians to represent Jefferson at the distinguished 2006 Southern Surgical Association
Meeting in Florida last November, where she presented some of her recent findings. It is their goal to
leverage this work in the lab to ensure that patients survive pancreatic cancer in increasing numbers and
go on to live long and healthy lives.
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Changing Lives Through Research

On the job
Donna Guinto, C-TAGME
Certified Training Administrator
of Graduate Medical Education
Programs
Donna Guinto is a 22-year employee
of Jefferson who has worked as the
Coordinator of the Surgical Residency
Program since 1994. She manages
the administrative and supervisory
activities of the 51-resident program.

Jonathan Brody, PhD and Hwyda Arafat, MD, PhD, conduct research that will lead to new
pancreatic cancer treatment options.
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How do you prepare for selecting
next year's residents?
In September, I begin downloading
applications. I do the preliminary
screening with the attendings doing
the final review. This year we received
close to 1100 applications. It's a
highly competitive process, with only
six slots available each year.

Donna Guinto in front of “The Board” —
hundreds of photographs documenting
the lives of past and present residents.

What qualities do you seek in
an applicant?
In addition to academic achievement,
preparedness, and communications skills,
we select candidates based on qualities
such as motivation, honesty, and integrity.
We look for team players — people
whose determination is fueled
by a personal commitment to helping
others — patients and colleagues alike.
How do residents benefit from
Jefferson's rich academic tradition?
Jefferson was the second hospital in
the U.S. to be directly associated with
a medical school — a real pioneer in

A patient's tumor is collected during surgery
and then studied in the lab to understand its
specific genetics. Dr. Brody seeks to use this
information to develop anti-cancer therapies
through medication that will be suited to the
individual patient.
“By studying a tumor's genesis, we can
begin to understand the series of events that
led up to making a cell cancerous,” he says.
“We will then have isolated the molecular
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better, more targeted, and sophisticated
approach for drug therapies.” Dr. Brody
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combining patient care with formal
education. In the mid-1850s, the
department prospered under the
leadership of Samuel D. Gross, MD,
known then as the “Emperor of
American Surgery.” Our faculty carry
on his legacy of surgical innovation
and passion for clinical education.
What are some of skills that your
job requires?
Multitasking – I manage the logistics
of the program such as residents’
work hours and schedules and
monitor accreditation, board, and
institutional requirements. I document
the evaluation processes and counsel
residents in solving problems in their
personal and professional lives. It's
a big job, but it comes with great
satisfaction, too.
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